The update is based on data from the FLEX study in patients with HR-positive, HER2-negative early-stage breast cancer.

The firm filed data from the Phase III VIKTORIA-1 trial, which evaluated gedatolisib with fulvestrant with or without a CDK4/6 inhibitor.

CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.

All patients with autoimmune hemolytic anemia in a small study initially achieved remission, though two eventually relapsed, ...

The companies struck the deal as Atsena prepares to initiate enrollment of a pivotal cohort of its lead program in XLRS.